A Randomized Comparison of Danazol and Leuprolide Acetate Suppression of Serum-Soluble CD23 Levels in Endometriosis
article
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This randomized trial found that both danazol and leuprolide acetate injections suppressed elevated serum-soluble CD23 levels in women with endometriosis compared to healthy controls.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In Brief Objective To determine the effects of treatment with danazol and leuprolide acetate depot on serum-soluble CD23 concentrations in women with endometriosis. Methods This randomized trial involved 20 women 18–42 years old with regular menses and known pelvic endometriosis who were recruited from a university hospital between 1993 and 1998. Ten women took 200 mg of danazol three times daily for 6 months, and the remaining ten were given 3.75 mg of leuprolide acetate depot every 28 days for 6 months. Blood-soluble CD23 levels were measured before treatment, during the last 15 days of the 6-month treatment course, and 3 months after treatment. Only one blood sample was taken from ten women without endometriosis, between the 5th and 7th days of their menstrual cycles. For statistical analysis, we used independent and paired t tests with the Pearson correlation coefficient. Results Soluble CD23 levels were significantly higher in women with endometriosis before treatment than in ten normal controls. Levels decreased significantly during treatment with either danazol or leuprolide acetate. Three months after treatment, soluble CD23 values remained lower than before treatment. There was no correlation between soluble CD23 concentrations and severity of endometriosis. Conclusion Our findings suggest that endometriosis increases soluble CD23 levels, which can be suppressed with either danazol or leuprolide acetate injection. Danazol and leuprolide acetate depot given for 6 months to women with endometriosis suppress levels of soluble CD23.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (16)
- Angiogenic activity of peritoneal fluid from women with endometriosis via openalex
- Deficient cellular immunity in endometriosis via openalex
- Endometriosis: Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection* via openalex
- Endometriosis: Soluble CD23 protein in the peritoneal fluid of patients with endometriosis via openalex
- Immunosuppressive effects of danazol in vitro via openalex
- Luteinized unruptured follicle in the early stages of endometriosis as a cause of unexplained infertility via openalex
- W2041896207 via openalex
- W2001649279 via openalex
- W1964770018 via openalex
- W2326993768 via openalex
- W2400534755 via openalex
- W1514549604 via openalex
- W2412739212 via openalex
- W2415597826 via openalex
- W2028712686 via openalex
- W2477008945 via openalex
Cited by (6)
- Avaliação de dois biomarcadores e de escores de dor pélvica crônica associada à endometriose em usuárias do implante com etonogestrel e do sistema intrauterino com levonorgestrel de 52 mg por 24 meses; e avaliação das vivências dos parceiros destas mulheres após o tratamento 2022
- Avaliação de biomarcadores em mulheres com endometriose e dor usuárias do implante liberador de etonogestrel ou sistema intrauterino liberador de levonorgestrel = Assessment of biomarkers among women with endometriosis-associated pain users of the etonogestrel-releasing contraceptive implant or 52-mg levonorgestrel releasing intrauterine system: randomized clinical trial 2018
- Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial 2018
- Avaliação do CA-125 e do CD-23 solúvel em pacientes com endometriose pélvica 2011
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- The possible anti‐inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot 2001
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-08-09T06:42:26.407065+00:00
License: CC0
· commercial use OK